User profiles for T. Leal
Teresinha LealUniversité Catholique de Louvain Verified email at uclouvain.be Cited by 3748 |
Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy
Cystic fibrosis is the most common life-threatening recessively inherited disease in Caucasians.
Due to early provision of care in specialized reference centers and more comprehensive …
Due to early provision of care in specialized reference centers and more comprehensive …
Leptomeningeal metastasis: challenges in diagnosis and treatment
T Leal, JE Chang, M Mehta… - Current cancer therapy …, 2011 - ingentaconnect.com
As therapeutic options and supportive care for the treatment of neoplastic disease have
improved, there has been an associated increase in the incidence of leptomeningeal disease. In …
improved, there has been an associated increase in the incidence of leptomeningeal disease. In …
[HTML][HTML] Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
…, M O'Brien, S Rao, K Hotta, TA Leal… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier:
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier:
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses
on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic …
on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic …
[HTML][HTML] Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …
shown clinical activity in pretreated patients with several tumor types, including colorectal …
[HTML][HTML] Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and …
…, F Orlandi, J Alatorre-Alexander, T Leal… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE: IMpower133 (ClinicalTrials. gov identifier: NCT02763579), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines
…, M Hennon, RP Lackner, M Lanuti, TA Leal… - Journal of the National …, 2021 - jnccn.org
Medicine (ACCME): NCCN designates this journal-based CME activity for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with …
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with …
NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
NCCN guidelines insights: non–small cell lung cancer, version 5.2018
… Leal The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of
Colorado Cancer Center; University of Washington/Seattle Cancer Care Alliance; Huntsman …
Colorado Cancer Center; University of Washington/Seattle Cancer Care Alliance; Huntsman …
[HTML][HTML] First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small-cell …
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small-cell …